You are leaving our website

or Decline


("Alliance" or the "Group")

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, is pleased to announce its results for the year ended 31 December 2013.

Financial Highlights

  • Revenue up 1% to £45.5m (2012: £44.9m)
  • Pre-tax profit up 11% to £12.0m (2012: £10.8m)
  • Basic EPS up 6% to 3.82p (2012: 3.61p)
  • Free cash flow of £8.4m (2012: £11.0m)
  • Net bank debt of £25.0m (2012: £21.8m)
  • Low gearing with Debt to EBITDA ratio of 1.6 times*
  • Proposed dividend:
    • Final dividend up 10% to 0.605p per share (2012: 0.55p)
    • Full year dividend up 10% to 0.908p per share (2012: 0.825p)

* including pro forma EBITDA of acquisitions

Operational Highlights

  • Three acquisitions of products since June 2013 with annualised gross margin of £2.6m
  • France and Germany both now trading profitably
  • Hydromol continues good growth, achieving year on year revenue growth of 12%
  • New packaging equipment for Ashton & Parsons Infants’ Powders now operational, with production volumes ramping-up

“It has been very pleasing to see Alliance return to double-digit profit growth in 2013. Given the strength of our portfolio, the acquisitions made in the past couple of years and the healthy pipeline of opportunities we are seeing, we are confident of good revenue and profit growth over the next few years. We plan to gain momentum from further acquisitions during 2014.”

Michael Gatenby, Alliance’s Chairman


Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer

Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black

Investec Bank plc + 44 (0)20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Tejas Padalkar

26 Mar 2014 Preliminary Results for the year ended 31 December 2013 (357KB PDF)